![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by TriedEveryMedication on November 9, 2011, at 11:29:30
currently in phase II trials:
GLYX-13 preclinical data presented at a major medical meeting showed that it demonstrated:
Robust antidepressant-like activity.
-An immediate onset of effectthe antidepressant effects of GLYX-13 were evident within 20 minutes of administering a single dose.
-A long-acting duration of effectdemonstrating an antidepressant-like effect lasting at least two weeks after a single dose.
-No signs of CNS-related side effects, achieving a therapeutic index of 500 or morean unprecedented result for drugs targeting the NMDA receptor.
Posted by ihatedrugs on November 11, 2011, at 22:42:09
In reply to immediate acting AD in the new drug pipeline?, posted by TriedEveryMedication on November 9, 2011, at 11:29:30
Posted by Chairman_MAO on November 15, 2011, at 6:10:22
In reply to immediate acting AD in the new drug pipeline?, posted by TriedEveryMedication on November 9, 2011, at 11:29:30
Thanks for the tip. At this point I take such claims with a grain of salt, but it looks interesting.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.